NRC Health Proceeds from Lines of Credit
NRC Health (NRC) reported Proceeds from Lines of Credit of $22.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-04
- NRC Health proceeds from lines of credit for the quarter ending 2026-06-30 was $19.50M, a 2.50% decline year-over-year.
- NRC Health proceeds from lines of credit for the quarter ending 2026-03-31 was $2.50M, a 68.75% decline year-over-year.
- NRC Health proceeds from lines of credit for the quarter ending 2025-12-31 was $4.00M, a 61.90% decline year-over-year.
- NRC Health proceeds from lines of credit for the quarter ending 2025-09-30 was $5.00M, a 67.74% decline year-over-year.
- NRC Health proceeds from lines of credit for fiscal 2025 was $37.00M, a 25.25% decline from fiscal 2024.
- NRC Health proceeds from lines of credit for fiscal 2024 was $49.50M, a 230.00% increase from fiscal 2023.
- NRC Health proceeds from lines of credit for fiscal 2023 was $15.00M.
- NRC Health proceeds from lines of credit for fiscal 2022 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $22.00M 10-Q · filed 2026-08-04 | $26.00M derived: sum of 3 quarters · filed 2026-08-04 | $31.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-06 | $6.50M derived: sum of 2 quarters · filed 2026-05-06 | $11.50M derived: sum of 3 quarters · filed 2026-05-06 | $31.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $9.00M derived: sum of 2 quarters · filed 2026-03-05 | $29.00M derived: sum of 3 quarters · filed 2026-08-04 | $37.00M 10-K · filed 2026-03-05 |
| 2025-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $25.00M derived: sum of 2 quarters · filed 2026-08-04 | $33.00M 10-Q · filed 2025-11-07 | $43.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $28.00M 10-Q · filed 2026-08-04 | $38.50M derived: sum of 3 quarters · filed 2026-08-04 | $54.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $8.00M 10-Q · filed 2026-05-06 | $18.50M derived: sum of 2 quarters · filed 2026-05-06 | $34.00M derived: sum of 3 quarters · filed 2026-05-06 | $44.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $26.00M derived: sum of 2 quarters · filed 2026-03-05 | $36.50M derived: sum of 3 quarters · filed 2026-03-05 | $49.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | $15.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $26.00M derived: sum of 2 quarters · filed 2025-11-07 | $39.00M 10-Q · filed 2025-11-07 | $49.00M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $10.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $23.50M 10-Q · filed 2025-08-08 | $33.50M derived: sum of 3 quarters · filed 2026-03-05 | $38.50M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $13.00M 10-Q · filed 2025-05-09 | $23.00M derived: sum of 2 quarters · filed 2026-03-05 | $28.00M derived: sum of 3 quarters · filed 2026-03-05 | $28.00M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $15.00M derived: sum of 2 quarters · filed 2026-03-05 | $15.00M derived: sum of 3 quarters · filed 2026-03-05 | $15.00M 10-K · filed 2026-03-05 |
| 2023-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $5.00M derived: sum of 2 quarters · filed 2024-11-08 | $5.00M 10-Q · filed 2024-11-08 | $5.00M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 10-K · filed 2025-03-17 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $4.50M derived: sum of 2 quarters · filed 2022-03-04 | $12.50M derived: sum of 3 quarters · filed 2022-03-04 | $21.00M 10-K · filed 2022-03-04 |
| 2019-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $12.50M derived: sum of 2 quarters · filed 2020-11-06 | $21.00M 10-Q · filed 2020-11-06 | $21.00M derived: sum of 4 quarters · filed 2021-03-05 |
| 2019-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $16.50M 10-Q · filed 2020-08-07 | $16.50M derived: sum of 3 quarters · filed 2021-03-05 | $18.00M derived: sum of 4 quarters · filed 2021-03-05 |
| 2019-03-31 | $8.50M 10-Q · filed 2020-05-08 | $8.50M derived: sum of 2 quarters · filed 2021-03-05 | $10.00M derived: sum of 3 quarters · filed 2021-03-05 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $1.50M derived: sum of 2 quarters · filed 2021-03-05 | $2.50M 10-K · filed 2021-03-05 | |
| 2018-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.50M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $1.00M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |